Transforming the prostatic tumor microenvironment with oncolytic virotherapy

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA. Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2010;28:1099–105. doi:10.1200/JCO.2009.25.0597. PMID:20100959.
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94. doi:10.1200/JCO.2005.04.5252. PMID:16809734.
   PubMed Web of Science ®Google Scholar
• Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer. 2012;12:289–97. doi:10.1038/nrc3223. PMID:22378189.
   PubMed Web of Science ®Google Scholar
• Ren R, Koti M, Hamilton T, Graham CH, Nayak JG, Singh J, Drachenberg DE, Siemens DR. A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J. 2016;10:60–5. doi:10.5489/cuaj.3418. PMID:26977209.
   PubMed Web of Science ®Google Scholar
• Gajewski TF. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015;42:663–71. doi:10.1053/j.seminoncol.2015.05.011. PMID:26320069.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74–80. doi:10.1126/science.aaa6204. PMID:25838376.
   PubMed Web of Science ®Google Scholar
• Vesalainen S, Lipponen P, Talja M, Syrjänen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994;30A:1797–803. doi:10.1016/0959-8049(94)E0159-2.
   PubMed Web of Science ®Google Scholar
• Hussein M-RA, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol. 2009;86:108–13. doi:10.1016/j.yexmp.2008.11.010. PMID:19111537.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu Y-M, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297–303. doi:10.1038/nature23306. PMID:28783718.
   PubMed Web of Science ®Google Scholar
• Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biol Ther. 2016;17:1213–20. doi:10.1080/15384047.2016.1235666. PMID:27791459.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559–67. doi:10.1038/nrc3770. PMID:24990523.
   PubMed Web of Science ®Google Scholar
• Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, Bell JC, McCart JA, Mahoney D, Stojdl DF, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010;18:1440–9. doi:10.1038/mt.2010.103. PMID:20551913.
   PubMed Web of Science ®Google Scholar
• Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, et al. Maraba Virus as a Potent Oncolytic Vaccine Vector. Mol Ther. 2014;22:420–9. doi:10.1038/mt.2013.249. PMID:24322333.
   PubMed Web of Science ®Google Scholar
• Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, et al. Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer Immunol Res. 2017;5:847–59. doi:10.1158/2326-6066.CIR-17-0102. PMID:28912369.
   PubMed Web of Science ®Google Scholar
• Le Boeuf F, Selman M, Son HH, Bergeron A, Chen A, Tsang J, Butterwick D4 Arulanandam R, Forbes NE, Tzelepis F, et al. Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma. Int J Cancer. 2017;141:1257–64. doi:10.1002/ijc.30813. PMID:28568891.
   PubMed Web of Science ®Google Scholar
• Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, et al. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci. 1999;96:14523–8. doi:10.1073/pnas.96.25.14523. PMID:10588738.
   PubMed Web of Science ®Google Scholar
• Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine Six-Transmembrane Epithelial Antigen of the Prostate, Prostate Stem Cell Antigen, and Prostate-specific Membrane Antigen Prostate-specific Cell-Surface Antigens Highly Expressed in Prostate Cancer of Transgenic Adenocarcinoma Mouse Prostate Mice. Cancer Res. 2001;61:5857–60. PMID:11479226.
   PubMed Web of Science ®Google Scholar
• Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Ritter E, Gnjatic S, Kristiansen G, Moch H, Knuth A, et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res. 2010;16:3562–70. doi:10.1158/1078-0432.CCR-09-3136. PMID:20519358.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3. doi:10.2202/1544-6115.1027. PMID:16646809.
   PubMedGoogle Scholar
• Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol. 2015;11:2137–48. doi:10.2217/fon.15.120. PMID:26235179.
   PubMed Web of Science ®Google Scholar
• Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013;2:e25961. doi:10.4161/onci.25961. PMID:24083084.
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Lichty BD, Bell JC. Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine. 2016;9:31–6. doi:10.1016/j.ebiom.2016.06.046. PMID:27407036.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng K-W. Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther. 2017;25:1107–16. doi:10.1016/j.ymthe.2017.03.026. PMID:28392162.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263–75. doi:10.1016/S1535-6108(03)00241-1. PMID:14585354.
   PubMed Web of Science ®Google Scholar
• Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao W-Q. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci. 2002;99:2830–5. doi:10.1073/pnas.052705299. PMID:11880635.
   PubMed Web of Science ®Google Scholar
• Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, et al. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell. 2015;28:210–24. doi:10.1016/j.ccell.2015.06.009. PMID:26212250.
   PubMed Web of Science ®Google Scholar
• Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol. 2016;16:741–50. doi:10.1038/nri.2016.99. PMID:27667712.
   PubMed Web of Science ®Google Scholar
• Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D, et al. Frequent Inactivation of PTEN/MMAC1 in Primary Prostate Cancer. Cancer Res. 1997;57:4997–5000. PMID:9371490.
   PubMed Web of Science ®Google Scholar
• Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, Ong C, Jia W, Rennie PS. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res. 2010;70:1367–76. doi:10.1158/0008-5472.CAN-09-2377. PMID:20145134.
   PubMed Web of Science ®Google Scholar
• Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, et al. Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. J Immunol. 2016;196:4587–95. doi:10.4049/jimmunol.1600106. PMID:27183620.
   PubMed Web of Science ®Google Scholar
• Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform. 2015;53:405–14. doi:10.1016/j.jbi.2014.11.003. PMID:25464113.
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez Mde la L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007;67:1344–51. doi:10.1158/0008-5472.CAN-06-2996. PMID:17283172.
   PubMed Web of Science ®Google Scholar
• Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, Raitano AB, Jia XC, Gudas JM, Kanner SB, et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 2007;67:5798–805. doi:10.1158/0008-5472.CAN-06-3849. PMID:17575147.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Herbert JMJ, Lodhia P, Bradford J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S, et al. Identification of novel vascular targets in lung cancer. Br J Cancer. 2015;112:485–94. doi:10.1038/bjc.2014.626. PMID:25535734.
   PubMed Web of Science ®Google Scholar
• Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, Kakizaki H, Tateno M. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J Urol. 2010;183:2036–44. doi:10.1016/j.juro.2009.12.094. PMID:20303532.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Kassambara A, Hose D, Klein B. STEAP1 is overexpressed in cancers: A promising therapeutic target. Biochem Biophys Res Commun. 2012;429:148–55. doi:10.1016/j.bbrc.2012.10.123. PMID:23142226.
   PubMed Web of Science ®Google Scholar
• Gomes IM, Maia CJ, Santos CR. STEAP proteins: from structure to applications in cancer therapy. Mol Cancer Res. 2012;10:573–87. doi:10.1158/1541-7786.MCR-11-0281. PMID:22522456.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee J-B, Lee GK, Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. The Prostate. 2009;69:938–48. doi:10.1002/pros.20942. PMID:19267351.
   PubMed Web of Science ®Google Scholar
• Cappuccini F, Stribbling S, Pollock E, Hill AVS, Redchenko I. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016;65:701–13. doi:10.1007/s00262-016-1831-8. PMID:27052571.
   PubMed Web of Science ®Google Scholar
• Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010;28:3548–57. doi:10.1016/j.vaccine.2010.03.007. PMID:20304037.
   PubMed Web of Science ®Google Scholar
• Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44–51. doi:10.1016/j.coi.2015.12.007. PMID:26796069.
   PubMed Web of Science ®Google Scholar
• Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, et al. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017;31:194–207. doi:10.1016/j.ccell.2017.01.004. PMID:28196594.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013. PMID:21376230.
   PubMed Web of Science ®Google Scholar
• Danila DC, Szmulewitz RZ, Baron AD, Higano CS, Scher HI, Morris MJ. A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol. 2014;32:5024-.
   Google Scholar
• Shim KG, Zaidi S, Thompson J, Kottke T, Evgin L, Rajani KR, Schuelke M, Driscoll CB, Huff A, Pulido JS, et al. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Mol Ther. 2017;25:962–75. doi:10.1016/j.ymthe.2017.01.023. PMID:28237836.
   PubMed Web of Science ®Google Scholar
• Ganesan A-P, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18:940–950. doi:10.1038/ni.3775. PMID:28628092.
   PubMed Web of Science ®Google Scholar
• Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint\sVictor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell. 2016;167:1540–1554.e12. doi:10.1016/j.cell.2016.11.022. PMID:27912061.
   PubMed Web of Science ®Google Scholar
• Sheu B-C, Chiou S-H, Lin H-H, Chow S-N, Huang S-C, Ho H-N. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res. 2005;65:2921–9. doi:10.1158/0008-5472.CAN-04-2108. PMID:15805295.
   PubMed Web of Science ®Google Scholar
• Sola C, Arnoux T, Chanuc F, Fuseri N, Rossi B, Gauthier L. Abstract 2342: NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model. Cancer Res. 2016;76:2342-. doi:10.1158/1538-7445.AM2016-2342.
   Web of Science ®Google Scholar